BioSpace News Archive

Preparations Underway to Activate Clinical Trial Sites and Enroll Patients in the REGAL Study in France, Germany and Greece by End of Second Quarter 2021

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the first quarter ended March 31, 2021

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended March 31, 2021 and provided a business update

The bioscience industry provides direct and indirect employment of 47,000 jobs in Oregon, showing substantial growth in the past decade.

Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointment of Brian C. Bock as the Company’s Chief Financial Officer (CFO) effective immediately.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announced that China’s National Medical Products Administration

Australian pharmaceutical group Phebra congratulates the Australasian Leukaemia and Lymphoma Group on the release of their abstract EP433 at the virtual European Hematology Association 2021 Conference.

Applied DNA Sciences, Inc., clarifies the scope of its newly authorized asymptomatic serial screening indication for its Linea COVID-19 Assay Kit and certain information contained in its previously disseminated 12 May 2021 press release relating to the U.S. Food and Drug Administration’s grant of a re-issued Emergency Use Authorization that expands the Assay Kit for asymptomatic serial screening testing.

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring systems for people with diabetes, reported financial results for the quarter ended March 31, 2021.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.